Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has announced its application for a grant from the ALS Association to fund a clinical trial for its lead candidate, intranasal foralumab, which shows promise in treating amyotrophic lateral sclerosis (ALS). This grant, part of the Hoffman ALS Clinical Trial Awards Program, would support a study aimed at advancing treatment options for ALS using intranasal foralumab. The company is optimistic about the potential of this therapy to improve the lives of patients with ALS and other neurodegenerative diseases.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
